STOCK TITAN

REGENXBIO to Host Conference Call on May 4 to Discuss First Quarter 2022 Financial Results and Recent Operational Highlights

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 4, 2022, at 4:30 p.m. ET to discuss its financial results for Q1 2022 and operational highlights. Interested parties can access the call via phone or a live webcast on the company's website. REGENXBIO focuses on gene therapy, utilizing its proprietary NAV Technology Platform, which includes rights to over 100 novel AAV vectors applicable across various therapeutic areas.

Positive
  • Announcement of a conference call to discuss upcoming financial results.
  • Utilization of the NAV Technology Platform with exclusive rights to over 100 AAV vectors.
Negative
  • None.

ROCKVILLE, Md., April 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2022, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 5581898. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-4-to-discuss-first-quarter-2022-financial-results-and-recent-operational-highlights-301533981.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO announce its Q1 2022 financial results?

REGENXBIO will announce its Q1 2022 financial results on May 4, 2022.

How can I participate in the REGENXBIO conference call?

Participants can join the call by dialing (855) 422-8964 domestically or (210) 229-8819 internationally, entering passcode 5581898.

What is the focus of REGENXBIO's NAV Technology Platform?

The NAV Technology Platform focuses on gene therapy, providing exclusive access to over 100 novel AAV vectors.

Where can I find the webcast of the REGENXBIO conference call?

The live and recorded webcast can be accessed on the Investors section of REGENXBIO's website.

REGENXBIO Inc.

NASDAQ:RGNX

RGNX Rankings

RGNX Latest News

RGNX Stock Data

510.79M
45.67M
7.39%
92.25%
9.91%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ROCKVILLE